Although commonly assessed in the context of microcytosis or sickling syndrome screening, hemoglobin mutations may not be as readily considered as a cause of other symptoms. These include macrocytosis with or without anemia, chronic or episodic hemolysis, neonatal anemia, erythrocytosis, cyanosis/hypoxia and methemoglobinemia/sulfhemoglobinemia. Hemoglobin disorders commonly interfere with the reliability of Hb A1c measurement. Because the clinical presentation can be varied and the differential diagnosis broad, a systematic evaluation guided by signs and symptoms can be effective. A tertiary care reference laboratory is particularly challenged by the absence of pertinent clinical history and relevant laboratory findings, and appropriate use of resources in a data vacuum can be problematic. To address these issues, our laboratory has constructed testing panels with a tiered strategy utilizing screening assays that detect the most common causes and reflexing additional assays that assess less common etiologies. See Figure 1 . Our testing algorithm panels include a rapid hemoglobin fraction monitoring test, a generic diagnostic hemoglobin electrophoresis profile, and more specific diagnostic evaluations for microcytic anemia, hereditary hemolytic anemia, methemoglobinemia and sufhemoglobinemia and erythrocytosis. Use of these testing strategies has facilitated the identification of rare and complex hemoglobin disorders from a wide variety of ethnic groups, including over 500 distinct named alpha, beta and gamma variants (of which 60+ were novel variants at the time of first detection), 99 beta thalassemia mutations and greater than 20 large deletional beta globin cluster deletion subtypes.
Introduction
Hemoglobinopathy evaluation is undertaken in a wide range of clinical situations which include newborn, prenatal or preconception screening, diagnostic testing to explain specific clinical signs and symptoms, and monitoring of hemoglobin (Hb) fractions after therapy. This varied range of test indications complicates a uniform streamlined approach to hemoglobin testing. Cost effective resource utilization requires knowledgeable application of the varied methods available and their complementary strengths and limitations to select tests best suited to answer the clinical need. In the tertiary reference laboratory setting, understanding the goal of the ordering provider and therefore the optimal extent of testing is challenging. Accurately relating the particular clinical question helps laboratorians process samples appropriately but this simple and basic information is too often not adequately communicated in real testing situations. Because the indications for hemoglobin testing are so wide-ranging, our laboratory approaches hemoglobinopathy testing in a tiered approach. See Figure 2 .
Methods and Discussion
The least complex clinical situation encountered in hemoglobin testing is the monitoring of a previously confirmed hemoglobin disorder. Monitoring is frequently used in sickle cell disorder patients with recent transfusion or hydroxyurea therapy to quantify Hb A, Hb F and the abnormal variant(s). This can be rapidly accomplished using a single detection method that reliably quantitates the variant percentage. We use high performance liquid chromatography (HPLC) or capillary electrophoresis (CE) for this purpose.
The next level of complexity is a diagnostic generic hemoglobin evaluation. This is a test that carries the most ambiguity regarding the level of testing required to answer a clinical question. It is designed as a diagnostic test which detects all of the most common Hb variants, quantitates Hb A 2 for the diagnosis of beta thalassemia minor and guides further testing for uncommon hemoglobin disorders. This heavily relies upon adequate communication from referring providers for proper interpretation and utilization management. Communication can be a written information sheet or electronic comment field to relay complete blood count (CBC) values, test indication/clinical suspicion, clinical/family history, ethnicity, and data regarding recent therapeutic confounders such as transfusion or hydroxyurea administration. Our laboratory utilizes HPLC [1] and CE [2] simultaneously as screening methods. If normal tracings are obtained and no further indication is known to be present, the result is released as negative with a caution statement that addresses the types of conditions that further evaluation could be considered. If indicated, additional tests are performed according to the possible identification of the disorder suspected. These can include sickle solubility, isoelectric focusing, hemoglobin stability (heat and isopropanol), flow cytometry for Hb F red cell distribution, mass spectrometry (MS) and molecular studies to include DNA sequencing of the alpha, beta and gamma globin genes and MLPA analysis of alpha and beta globin cluster loci. Because many methods are available, judicious use of the testing options requires clinical information and knowledge of the strengths and limitations of the methods available for diagnosis. To aid in the diagnosis of very complex hemoglobin disorders, a more comprehensive testing profile is offered in which HPLC and CE results are correlated with ferritin levels, possible deletional alpha thalassemia testing, and red blood cell (RBC) indices. This allows for incorporating iron deficiency and alpha thalassemia status and assumes an indication for more extensive investigations to explain the phenotype. Multifactorial causes are addressed, such as beta thalassemia trait that shows a more severe phenotype than expected, or complex Hb E disorders. This strategy has identified many electrophoretically silent clinically significant variants (Hb Adana, Hb Bronovo, Hb Taybe) that may be missed by our routine hemoglobin electrophoresis test offering.
Some indications for hemoglobin testing encompass a broader scope of RBC disorders. To address these needs we use panels focused on particular signs and symptoms, in particular, hemolysis, methemoglobinemia, or erythrocytosis. The panel that assays for hereditary causes of hemolysis includes hemoglobin (with frontline stability study testing), RBC enzyme and membrane disorder testing. It incorporates RBC enzyme activities and osmotic fragility/EMA binding assays for membrane disorders correlated with a review of the peripheral blood smear. The addition of the stability study screen identifies many electrophoretically silent unstable Hb variants. Another panel that focuses on methemoglobinemia and sulfhemoglobinemia performs HPLC and CE, methemoglobin and sulfhemoglobin levels and methemoglobin reductase (METR) [cytochrome b5 reductase 3] activity levels [3] . This provides for the identification of M-hemoglobin variants which were historically challenging to identify using previous methods but have characteristic patterns using the HPLC method. Elevated methemoglobin or sulfhemoglobin values prompt further investigation for a variant that can be subtle or silent by electrophoresis and HPLC, such as Hb Volga. In addition, this profile also assesses for METR deficiency-associated congenital methemoglobinemia.
Our laboratory has found great utility in a panel for the evaluation of hereditary erythrocytosis which includes frontline oxygen dissociation curve (p50) and MS testing [4] . Serum erythropoietin and p50 results efficiently guide reflex testing from the 19 different assays available for erythrocytosis. In our experience, hereditary erythrocytosis is commonly caused by high oxygen affinity hemoglobin variants (HOA) which are associated with a decreased p50 value. Many HOAs have neutral charge substitutions, do not separate from Hb A using multiple protein screening methods and can result in false negative cases. Simultaneously performing MS, HPLC and CE methods allows for the detection of all of the 79 distinct alpha and beta globin chain HOA variants we have seen in our laboratory (manuscript submitted for publication). In addition, the MS method enables an estimate of variant percentages in many cases that do not separate from Hb A by other methods. When a HOA is excluded, this panel tests for erythropoietin receptor (EPOR), 2,3-bisphosphogycerate mutase (BPGM) and oxygen sensing pathway mutations (HIF2A, PHD2 and VHL) as possible etiologies for the elevated hematocrit in an algorithmic fashion.
Conclusions
In summary, indications for the evaluation of hemoglobin disorders vary from the simple to the very complex. Laboratories at tertiary reference centers harbor extensive experience but suffer from a dearth of preanalytical information critical in the accurate interpretation and efficient triaging of appropriate testing for these disorders. Creating specific testing panels based on signs and symptoms allows assignment of implied indications for testing and utilize appropriate algorithms. These testing strategies allow efficient diagnoses of rare clinically significant hemoglobin disorders and decrease widespread indiscriminate testing that wastes resources. While continued suboptimal communication between clinical caregivers and laboratorians still result in missed opportuProceedings Book nities to identify all clinically significant variants, the use of these testing strategies in our laboratory has facilitated the identification of rare and complex hemoglobin disorders from a wide variety of ethnic groups, including over 500 distinct named alpha, beta and gamma variants (of which 60+ were novel variants at the time of first detection), 99 beta thalassemia mutations and greater than 20 large deletional beta globin cluster deletion subtypes [4] [5] [6] [7] [8] [9] [10] .
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